CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


MaravirocWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug2180 Saline containing 1% Human serum albumin(solution without UC-MSCs) Wiki 1.00
drug2580 UC-MSCs Wiki 0.45

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D014777 Virus Diseases NIH 0.12
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Open-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2

Maraviroc, a C-C Chemokine Receptor 5 (CCR5) antagonist, is well-tolerated without significant side effects in its current use in patients with HIV. CCR5 antagonism prior to the 'second wave' of inflammatory mediator expression in SARS-CoV-2 may reverse lymphoid depletion and may alter cell trafficking of inflammatory cells, both increasing viral control capacity and dampening damage to lung tissue, respectively. This study seeks to establish whether one week of treatment with Maraviroc, used at its approved dosage for HIV, is safe and tolerable in patients with SARS-CoV-2.

NCT04435522 COVID Drug: Maraviroc

Primary Outcomes

Description: Rate of subjects who complete the 7-day course of Maraviroc without discontinuation for serious adverse event or death.

Measure: Rate of Completion

Time: 7 days

Description: Percent of patients at Day 7 from enrollment achieving reduction of two points on a seven-category ordinal scale (defined below). Ordinal scale: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities OR hospitalized pending disposition, not requiring COVID-related care; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring ECMO, invasive mechanical ventilation, or both; and, 7, death.

Measure: Clinical improvement at Day 7

Time: 7 days

Secondary Outcomes

Description: Measurement of Chi3l1 before, during and at completion of therapy.

Measure: Change in Chitinase 3-like 1(Chi3l1) (ng/mL)

Time: 7 days

Description: Measurement of IL-6 before, during and at completion of therapy.

Measure: Change in Interleukin-6 (IL-6) (pg/mL)

Time: 7 Days

Description: Measurement of CCL5 before, during and at completion of therapy.

Measure: Change in CCL5 (RANTES) (ng/mL)

Time: 7 Days

Description: 7-, 14- and 28-day all-cause-mortality

Measure: Mortality

Time: 28 days

Description: Time to improvement to Score of 2 or less (Days)

Measure: Time to Discharge

Time: 28 days

Measure: Days on mechanical ventilation

Time: 28 days


No related HPO nodes (Using clinical trials)